Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update

Autor:	Axel Hauschild, Alexander M.M. Eggermont, V. M. Vukovic, Steven J. O'Day
Rok vydání:	2010
Předmět:	chemistry.chemical_classification Cancer Research Reactive oxygen species business.industry medicine.disease_cause chemistry.chemical_compound Oncology chemistry Paclitaxel Apoptosis Cancer cell Cancer research Elesclomol Medicine Inducer Stage iv business Oxidative stress
Zdroj:	Journal of Clinical Oncology. 28:8550-8550
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2010.28.15_suppl.8550
Popis:	8550^ Background: Elesclomol is an investigational first-in-class oxidative stress inducer that increases reactive oxygen species in cancer cells leading to mitochondria-induced apoptosis. Methods:...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::121d75308877d6686717363688a13bef https://doi.org/10.1200/jco.2010.28.15_suppl.8550 Zobrazit plný text záznamu